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Abstract
Background: Arrhythmogenic cardiomyopathy (ACM) is an inherited genetic disorder, characterized by the
substitution of heart muscle with fibro-fatty tissue and severe ventricular arrhythmias, often leading to heart failure
and sudden cardiac death. ACM is considered a monogenic disorder, but the low penetrance of mutations
identified in patients suggests the involvement of additional genetic or environmental factors.
Methods: We used whole exome sequencing to investigate digenic inheritance in two ACM families where
previous diagnostic tests have revealed a PKP2 mutation in all affected and some healthy individuals. In family
members with PKP2 mutations we determined all genes that harbor variants in affected but not in healthy carriers
or vice versa. We computationally prioritized the most likely candidates, focusing on known ACM genes and genes
related to PKP2 through protein interactions, functional relationships, or shared biological processes.
Results: We identified four candidate genes in family 1, namely DAG1, DAB2IP, CTBP2 and TCF25, and eleven
candidate genes in family 2. The most promising gene in the second family is TTN, a gene previously associated
with ACM, in which the affected individual harbors two rare deleterious-predicted missense variants, one of which
is located in the protein’s only serine kinase domain.
Conclusions: In this study we report genes that might act as digenic players in ACM pathogenesis, on the basis of
co-segregation with PKP2 mutations. Validation in larger cohorts is still required to prove the utility of this model.
Keywords: Digenic inheritance, Arrhythmogenic cardiomyopathy, Exome sequencing, ACM, PKP2
Background
Arrhythmogenic cardiomyopathy (ACM) is a genetic dis-
order in which the ventricular myocardium is progres-
sively replaced by fibro-fatty tissue. Since this occurs
predominantly in the right ventricle, the disease is also
known as arrhythmogenic right ventricular cardiomyop-
athy (ARVC). ACM is associated with progressive heart
failure and severe ventricular arrhythmias, often leading
to sudden death, especially in young people and athletes
[1]. About half of the affected individuals harbor
mutations in one of the five genes of the cardiac desmo-
some (PKP2, JUP, DSP, DSG2, DSC2), of which mutations
in PKP2 are most common. Desmosomes are intercellular
junctions that confer strong cell–cell adhesion and pro-
vide a mechanical connection between cardiomyocytes.
Therefore, desmosomal defects can have deleterious ef-
fects on tissue integrity. In addition, desmosomal proteins
play an important role in signaling and regulation of cell
proliferation and differentiation [2]. In ACM, pathogenic
mechanisms include suppression of Wnt signaling and
activation of the Hippo pathway [3] leading to adipo-
genesis. Beside desmosomal genes, mutations in eight
additional genes (DES, PLN, TGFB3, CTNNA3, LMNA,
TMEM43, RYR2, and TTN) have been found to cause
ACM [1]. Recently, two studies reported FLNC and
CDH2 as possible novel causative genes for ACM [4, 5].
In most patients, ACM is inherited in an autosomal
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dominant mode with reduced penetrance (not all indi-
viduals with a causal mutation develop ACM) and vari-
able expressivity (the severity and the nature of the
symptoms may vary between affected individuals, even
if they have the same causal mutation).
Autosomal dominant mutations have only been identi-
fied in up to 60% of all ACM patients [1] suggesting the
existence of unknown mechanisms such as higher gen-
etic heterogeneity, modifier genes, or cross talk between
genetic background and environmental factors [6]. In
fact, three loci have been mapped in ACM linkage stud-
ies, for which the causal gene has not yet been identified:
ARVD3 (OMIM %602,086) at 14q12–32.3 [7], ARVD4
(OMIM %602,087) at 2q32.1–32.3 [8], and ARVD6
(OMIM %604,401) at 10p14-p12 [9]. In addition, the fre-
quency of variants associated with ACM has been found
to be much higher than expected given the phenotype
prevalence in the general population, suggesting that a
high number of these variants are not monogenic causes
of ACM [10]. In fact, recent reports have suggested
digenic inheritance as an alternative disease mechanism
of ACM [11–14]. In digenic inheritance the presence of
two variants in two different genes is required for the
manifestation of a clinical phenotype; in the absence of
one of these variants, the other variant might be benign.
For example, Xu et al. screened 198 ACM patients for
variants in the desmosomal genes. Of the 38 patients in
which PKP2 variants were detected, additional variants
in PKP2 itself (compound heterozygosity) were identified
in nine patients; variants in other desmosomal genes
(digenic inheritance) were identified in 13 patients. Re-
lated family members harboring a variant in just one of
these genes were unaffected by ACM. The authors con-
cluded that the disease was caused by compound hetero-
zygosity or digenic inheritance in these patients [12].
Rasmussen et al. investigated 12 families with variants in
DSG2. In three of these families, additional variants were
identified in the DSP gene in affected family members.
Only individuals with both variants in DSG2 and DSP
were affected by ACM, leading the authors to conclude
that low penetrance of desomosmal variants in ACM pa-
tients may also be explained by digenic inheritance [13].
Cooper et al. proposed that digenic inheritance may
occur as a result of variants in two genes encoding dif-
ferent subunits of the same protein (complex); two pro-
teins that interact functionally; are a receptor-ligand
pair; are a target gene and transcription factor; or com-
promise the same regulatory, biosynthetic, or degrada-
tive pathway [11]. Digenic inheritance is distinct from
modifier genes: in digenic inheritance, both variants in-
dividually usually do not lead to disease, whereas in
modifier genes one pathogenic variant is enhanced by a
putatively contributing variant of unknown significance
[15]. Non-genetic factors known to influence ACM
penetrance are age, male sex and intense physical activity
[16, 17].
We performed whole exome sequencing on two fam-
ilies, in which diagnostic tests have identified a PKP2
mutation in affected and healthy individuals. Assuming a
digenic mode of inheritance, we determined all genes,
where in addition to the observed PKP2 variant a second
causal variant was expected to be present in either the
affected individuals or the PKP2 carriers. Filtering and
prioritizing these genes, we determined four candidate
genes in the first, and eleven candidate genes for digenic
inheritance in the second family.
Methods
Subjects
In this study two Italian families comprising eight and
four individuals, respectively, were investigated. Two in-
dividuals in the first and one individuals in the second
family have been diagnosed with arrhythmogenic cardio-
myopathy (ACM) according to the diagnostic task force
criteria [18] (Table 1). Furthermore, previous clinically
certified molecular tests on known ACM related genes
have identified PKP2 variants in all affected and some
healthy family members (Fig. 1).
Family 1 (Fam1) consists of eight individuals in three
generations of which two are affected by ACM (Fam1.-
III.2 and Fam1.III.3). The five individuals Fam1.I.2,
Fam1.II.2, Fam1.III.1, Fam1.III.2, and Fam1.III.3 carry
the heterozygous one base-pair deletion NM_004572.
3(PKP2):c.2013delC, NP_004563.2(PKP2):p.Lys672Argf-
sTer12, which results in a premature stop codon after a
frameshift mutation.
Family 2 (Fam2) consists of two parents and their two
sons, one of which (Fam2.II.1) is affected by ACM. The
male patient Fam2.II.1, his brother Fam2.II.2 and their
mother Fam2.I.2 carry the heterozygous nine base pair
deletion NG_009000.1(PKP2):c.2569_2577 + 41del, which
crosses an exon/intron border.
In this study, ACM-diagnosed individuals are referred
to as affected, healthy individuals with a PKP2 mutation
are called carriers, and healthy individuals without a
PKP2 mutation are called healthy.
Details on the diagnostic genetic tests are given in the
Additional file 1.
Data generation and computational processing
Samples were prepared following the Nextera® Rapid
Capture Exome Enrichment kit protocol and were se-
quenced on two lanes of a HiSeq 2500 in paired end
mode (2 × 100). Reads were aligned with BWA [19] and
variants called with GATK [20], following the best prac-
tice recommendations. Variants were annotated with in-
formation from Ensembl [21], the ExAC project [22]
(allele frequency (AF), variants with AF < 0.01 are called
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rare), PROVEAN deleteriousness prediction scores
(variants with scores < −2.5 are called deleterious)
[23] (for SNPs and indels), and LR.PF3 pathogenicity pre-
diction scores [24] (for SNPs only). Copy number varia-
tions (CNVs) were called with XHMM [25].
MAESTROweb [26, 27] was used to predict the effect of
variants on protein stability based on protein structure,
where structure data were available. Sequence conserva-
tion was computed with ConSurf [28]. A detailed descrip-
tion is given in the Additional file 1.
Family-based gene selection
To investigate whether individuals in the two families
develop ACM if they carry the PKP2 mutation and a
variant that affects a second unknown gene, a set of pu-
tative causal genes was compiled in each family. All
genes were determined that have a least one variant that
meets the following three criteria: (i) The variant has a
consequence, that is classified as either “high” (transcript
ablation, splice acceptor variant, splice donor variant,
stop gained, frameshift variant, stop lost, start lost, tran-
script amplification) or “moderate” (inframe insertion,
inframe deletion, missense variant, protein altering vari-
ant) by Ensembl. (ii) The variant is either present in the
family’s affected individuals and not in any family’s PKP2
carrier individuals or it is present in the family’s PKP2
carrier individuals and not in any family’s affected indi-
viduals in either a dominant or a recessive mode. (iii)
The variant has a coverage of at least 10X in all affected
and carrier individuals.
In addition to the Fam1 and Fam2 family members, an
unrelated female ACM affected individual, her carrier
sister, and their carrier aunt, all carrying a heterozygous
PKP2 exon 4 deletion, were used to exclude variants as
described in (ii) (see Additional file 1 for details). Vari-
ants were not filtered based on allele frequency or
pathogenicity prediction. Furthermore, all genes were
determined that harbored copy number variations
(CNV; either a deletion or a duplication) in the affected
and carrier individuals applying the same genotype selec-
tion criteria as for variants.
Each family’s gene set was filtered to only include
genes expressed in the heart. The RNA gene dataset was
downloaded from the ProteinAtlas [29] version 15,
which contains gene expression levels of 45 cell lines
and 32 tissues based on RNA-seq. A gene was consid-
ered expressed in the heart, if it had an expression level
of at least 5 FPKM in the heart muscle in this dataset.
We call the genes/variants determined by these filtering
steps Fam1 genes/variants and Fam2 genes/variants.
This gene selection is visualized in Fig. 2.
ACM and PKP2-related genes
A set of 15 genes known to be involved in ACM was
created by literature review [4, 5, 30]. In particular, the
ACM gene set consists of the desmosomal genes PKP2,
JUP, DSP, DSG2, and DSC2 and the genes DES, PLN,
RYR2, TGFB3, TMEM43, TTN, CTNNA3, LMNA, FLNC,
and CDH2.
Since PKP2 is relevant for the development of ACM in
both families, we assumed that the second unknown
gene is directly related to PKP2 [11]. Following the prob-
able mechanisms of digenic inheritance described by
Cooper et al. [11], a set of PKP2-related genes was com-
piled based on the following five criteria. (i) The two
gene products form a protein complex. Gene complex
Fig. 1 Pedigrees of the two families analyzed in this study. Only labeled individuals were sequenced. +: Heterozygous variant, filled black
symbols: affected individuals; white symbols with +: carrier individuals; white empty symbols: healthy individuals. Left: Family 1 (Fam1); the blue +
symbol indicates the presence of the NM_004572.3(PKP2):c.2013delC variant, the orange + symbol indicates the presence of the four Fam1
variants ENSP00000312435.2(DAG1):p.Leu86Phe, ENSP00000263347.7(TCF25):p.Ser390Phe, ENSP00000259371.2(DAB2IP):p.Asp10Gly, ENSP00000357816.
5(CTBP2):p.Gly70Arg. Right: Family 2 (Fam2); the pink + symbol indicates the presence of the NG_009000.1(PKP2):c.2569_2577 + 41del variant, the
green + symbol indicates the presence of the ENSP00000434586.1(TTN):p.Gln24857His and the ENSP00000434586.1(TTN):p.Arg23483His variants
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data were downloaded from the BioPlex database [31]
version 4. Genes that interacted with PKP2 with a confi-
dence of at least 0.7 were selected. (ii) The two gene prod-
ucts interact functionally. PKP2 interactors were
downloaded from the STRING database [32] version 10
and the mentha database [33] version 2016–08-07.
STRING interactions were restricted to those with a confi-
dence of at least 0.7. The union of PKP2 interactors from
the two databases was selected. (iii) The two gene products
are transcription factor and target gene. The Ensembl
database [21] version 84 and ORegAnno database [34] (re-
lease 2015.12.22) were manually reviewed for transcription
factors of PKP2. (iv) The two gene products participate in
the same pathway. “Biological process” (BP) gene annota-
tions from the Gene Ontology [35] (GO) were used as an
approximation. All biological process annotations of PKP2
and all their annotated proteins were queried from the
GO database version 2016.7 using the Dintor GOAnnota-
tor tool [36]. Processes were restricted to those where at
least half of their annotated genes were expressed in the
heart and all genes annotated to these processes were se-
lected, creating a set of genes that share a biological func-
tion with PKP2. (v) The two genes are paralogs. Though
not specifically listed as a mechanism of digenic
inheritance, Cooper et al. discussed that paralogous genes
might provide a level of redundancy by resuming gene
function in case of a disruption [11]. Therefore, genes par-
alogous to PKP2 were queried from Ensembl 86.
The set of genes that meet all five criteria was named
the PKP2-related genes. Analogous to the Fam1 and
Fam2 gene sets, PKP2-related genes were restricted to
those expressed in the heart.
The intersection of Fam1 and Fam2 genes with the
PKP2-related genes was prioritized using the Dintor
MetaRanker tool [36], by equally weighting gene expres-
sion, number of variants, variant class (consequence
class “high” was rated higher than class “moderate”),
minimum ExAC allele frequency of the gene’s variant(s),
minimum PROVEAN score of the gene’s variant(s), bin-
ary prediction (neutral or deleterious) of this PROVEAN
score, and presence in a linkage region (see Fig. 2). The
LR.PFS3 model [24] was not used in the ranking since it
is not defined for indels.
Results
Whole exome sequencing
For each of the eight samples relevant to this study
(Fam1.I.2, Fam1.II.2, Fam1.III.1, Fam1.III.2, Fam1.III.3,
Fig. 2 Methods summary. Whole exome sequencing and variant calling was performed for each individual in both families. For each family,
genes are selected that have at least one variant with a high or moderate variant impact, that differ between healthy and affected PKP2 carriers,
that have a coverage of at least 10X, and that are expressed in the heart. These genes are filtered to include only genes related to ACM or PKP2
and are computationally prioritized. Results are presented in Table 2
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Fam2.I.2, Fam2.II.1, and Fam2.II.2), an average of 54.3
± 15.3 million reads was generated. The mean base
quality was well above 30Q at all read positions, yet a
drop in quality could be observed in the last 20 bases
of each read. Nearly all reads (99.9%) could be suc-
cessfully mapped to the human reference genome
GRCh37, resulting in a mean coverage of 24.4 ± 3.9X
at a mean mapping quality of 45.2 ± 0.8Q. On average,
85.1 ± 3.8% of the exonic target region was covered
with at least 10X.
Identification of candidate genes
The filtering strategy described in the Methods Section
and visualized in Fig. 2 resulted in 85 variants in 74 dis-
tinct genes in Fam1 and 242 variants in 212 distinct
genes in Fam2. The gene sets for both families obtained
by this filtering strategy are available as Additional file 1:
Table S1. No CNVs in either family met the selection
criteria. Since the number of genes per family was too
large to analyze in detail, we decided to restrict our ana-
lysis to known ACM related genes and then to PKP2-re-
lated genes.
From the 15 ACM-related genes, none was present in
the gene set of Fam1, while TTN was in the gene set of
Fam2 (Table 2). Specifically, the affected male patient
Fam2.II.1 and his healthy father Fam2.I.1 harbored three
distinct heterozygous missense variants in TTN. The
two rare variants ENSP00000434586.1:p.Gln24857His
(isoform N2B) and ENSP00000434586.1:p.Arg23483His
(isoform N2B) were predicted deleterious by PROVEAN
and LR.PFS3. Both variants were confirmed by Sanger
sequencing (see Additional file 1). The third TTN vari-
ant ENSP00000434586.1:p.Ile3716Val (isoform N2B) is
common, not conserved, and was predicted neutral by
PROVEAN and LR.PFS3. TTN encodes for titin, the lar-
gest human protein, which has over 300 highly repetitive
independently folding domains, including 152 immuno-
globulin like, 132 fibronectine 3 (Fn3), 19 Kelch, 14 tet-
ratricopeptide repeat, and 15 solenoid domains [37]. The
variant Arg23483His is located in the 125th of the 132
Fn3 domains (PF00041), while Gln24857His is located
inside titin’s only serine kinase domain (PF00069), a
structurally conserved protein domain that plays an im-
portant role in the regulation of cell proliferation, apop-
tosis and cell differentiation. The location of this variant
and other functional residues in the protein structure of
the kinase domain is visualized in Fig. 3. The mutated
residue Gln24857His is located opposite of the active site
and results in a charge and polarity change. The variant
was further predicted to destabilize the protein structure
by MAESTROweb (ΔΔG= 1.433, confidence = 0.8). In
addition, the wild type residue glutamine was highly con-
served in a multiple sequence alignment of homologous
sequences from 63 species computed by ConSurf.
In the next analysis step, we identified 311 genes related
to PKP2 following the criteria defined in the Methods sec-
tion: (i) Five genes form a complex with PKP2, (ii) 33
genes interact with PKP2, (iii) four genes are transcription
factors of PKP2, (iv) 275 genes are involved in one of 12
biological processes together with PKP2, (v) and three
genes are paralogs of PKP2. A list of these PKP2-related
genes is available as Additional file 1: Table S2. Four Fam1
genes and ten Fam2 genes were in the set of PKP2-related
genes and were prioritized based on their expression in
the heart, the number and type of variants, their allele fre-
quencies and deleteriousness prediction. These PKP2-re-
lated genes and variants of both families are summarized
in Table 2. The full table with additional, detailed annota-
tions is available as Additional file 1: Table S3.
Of the four PKP2-related genes DAG1, DAB2IP, and
CTBP2 in Fam1 are associated with PKP2 through the
GO BP process “negative regulation of cell migration”,
while TCF25 is associated with PKP2 through the GO BP
process “heart development”. The variants in all four
genes are predicted neutral by PROVEAN, and all but the
one in CTBP2 are rare. The highest ranking PKP2-related
gene in Fam1 is DAG1, which encodes for dystroglycan, a
central component of the dystrophin–glycoprotein com-
plex (DGC). Dystroglycan is post-translationally cleaved
into α- and β-dystroglycan subunits [38]. α-dystroglycan is
an extracellular protein involved in the interactions be-
tween DGC and extracellular matrix components, while
β-dystroglycan contains a single transmembrane domain
and a C-terminal cytoplasmic tail. The DAG1 candidate
substitution ENSP00000312435.2:p.Leu86Phe is located in
the α-dystroglycan N-terminal region, where the leucine
side chain is solvent exposed on the side of a Ig-like do-
main [39]. The position is in close proximity to Thr63,
identified as a O-glycosylation [40] (see Additional file 1:
Fig. S1). The variant was predicted to stabilize protein
structure by MAESTROweb (ΔΔG= −0.231, confidence =
0.9). For the other three candidate genes, no protein struc-
ture was available in PDB, so predictions with MAES-
TROweb could not be computed.
The highest ranking PKP2-related gene in Fam2 is the
interferon regulatory factor 1 (IRF1), which harbors a
rare, deleterious-predicted missense variant in the af-
fected male patient Fam2.II.1 and his healthy father
Fam2.I.1. IRF1 inhibits cell growth in coronary artery
smooth muscle cells [41]. Repression of IRF1 has lead to
a higher susceptibility to the formation of neointima
(scar tissue) following vessel injury in mice [41].
Discussion
In this study we investigated the genetic cause of ACM
in two families using whole exome sequencing. Since all
affected and some unaffected individuals were known to
harbor PKP2 variants, we investigated whether a second
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gene was involved in a digenic inheritance pattern, with
the second gene either causing ACM in the affected in-
dividuals together with PKP2, or compensating the effect
of the PKP2 variants in the carriers. We identified 74 and
212 genes in families 1 and 2, respectively, which carried
variants consistent with the mode of digenic inheritance.
To obtain results that can be easily interpreted, we re-
stricted our analysis to genes either associated with ACM
or related to PKP2. In family 1 we identified four genes
that are annotated with the same biological process as
PKP2. In family 2 we identified the ACM associated gene
TTN and ten genes related to PKP2 through a shared bio-
logical process or protein interactions (see Fig. 2).
Of the four PKP2-related Fam1 genes, the genes hom-
ologous to DAG1, TCF25, and CTBP2 have been linked to
cardiomyocyte proliferation or heart development in mice
and, in case of TCF25, also in human. DAG1 and TCF25
negatively regulate heart development, while a knock out
of CTBP2 leads to a lethal malformation of the heart in
mice. A variant in DAB2IP has been associated with cor-
onary heart disease in two studies, indicating that this
gene might also play a crucial rule for the normal func-
tioning of the heart. It has been reported that β-
dystroglycan, a protein product of DAG1, directly binds to
the Hippo pathway effector Yap to inhibit cardiomyocyte
proliferation in mice [42]. In particular, the Hippo path-
way and DGC cooperatively regulate tissue growth in
mouse hearts after injury. Yap and the Hippo pathway
have been directly implicated in ACM pathogenesis [30].
TCF25 (previously named NULP1) was suggested as a
transcription factor that negatively regulates the serum re-
sponse factor (SRF). SRF controls muscle differentiation
and cellular growth and regulates cardiac genes. SRF over-
expression has been shown to cause cardiomyopathy and
cardiac hypertrophy in mice. Therefore, TCF25 may func-
tion as a transcriptional repressor of SRF in human heart
development [43]. DAB2IP acts as a tumor suppressor
gene, and is inactivated by methylation in prostate and
breast cancers. A genome-wide association study found
the rs7025486 variant in DAB2IP associated with coronary
heart disease, which was replicated in a second study [44].
CTBP2 encodes two proteins, a transcriptional repressor
and a major component of synaptic ribbons. Silencing the
homologous Ctbp2 gene in mice causes defects in heart
morphogenesis and results in early embryonic lethality
[45]. Ctbp2-null mice show similar axial truncation
phenotypes as mice with mutations in some Wnt target
genes, suggesting that CTBP2 may be a regulator of Wnt-
mediated gene expression [45]. Indeed, CtBP2 acts as co-
repressor of C/EBPα, an early regulator of adipogenesis,
and target of the Wnt signaling pathway [46]. Further-
more, Sox6 has been found to bind Ctbp2 to repress the
fibroblast growth factor 3 [47] and Sox6 to regulate the
cardiac myocyte development in mice [48]. Although
none of the variants in these four genes are predicted to
be deleterious and the variant in DAG1 is even predicted
to stabilize protein structure, they could nevertheless
affect protein stability, flexibility, and interaction with the
other binding partners. However, in the present study we
could not find any indication that these genes may act to-
gether with PKP2 to cause the ACM phenotype in the af-
fected individuals of Fam1.
Since TTN is a known ACM associated gene, it is a
likely candidate in the second family. TTN encodes for
titin, the largest human protein with isoforms ranging
from about 27.000 to 36.000 amino acids. Titin is func-
tionally linked to the desmosome (and thereby to PKP2),
since titin filaments are a key component of sarcomeres
and connect to the transitional junction at the interca-
lated disk [8]. In a cohort of 38 ACM families, Taylor et
al. identified novel TTN mutations in 18% of the families
[8]. In addition to ACM, TTN has been associated with
dilated, hypertrophic, and restrictive cardiomyopathy
[49]; its association with hypertropic cardiomyopathy,
however, is still under debate [50]. The affected patient
Fig. 3 Structure of the titin kinase domain (PDB 1tki chain A).
Functional residues are represented as ball and stick, D24874 is the
catalytic aspartate. The ATP binding site includes residue K24783 as
well as the nearby yellow loop. The calcium/calmodulin binding helix
is colored blue, the helix in orange blocks the ATP binding site in this
autoinhibited conformation. Residue Q24857 is solvent exposed on the
side opposite to the functional residues
König et al. BMC Medical Genetics  (2017) 18:145 Page 9 of 12
Fam2.II.1 and his father both harbor two rare heterozy-
gous missense variants that are predicted deleterious.
The Gln24857His variant is located in titin’s only kinase do-
main at a conserved position and is predicted to destabilize
protein structure, while Arg23483His is located in one of
the 132 Fn3 domains. Therefore, the Gln24857His variant
is more likely to impair titin function than the Arg23483His
variant, even though disease causal variants in repetitive
titin domains have been reported [8]. Studies with trans-
fected cell lines have shown that heterozgyous mutations,
in contrast to homozygous mutations, still allow for func-
tional sarcomeres but may alter the organizational charac-
teristics and impair the normal cardiac function [49]. These
findings agree well with the hypothesis that either one or
both of these variants alter the structure of titin and only
lead to ACM in combination with the PKP2 mutation.
In addition to the genes described here in more detail,
there are other promising candidates for the second
causal gene in Fam2 (see Table 2). For example, of the
PKP2-related genes, NOTCH2 and SCN5A harbor one of
two compound heterozygous variants that have been re-
ported to cause congenital heart disease and isolated
conduction disease, respectively [51, 52]; DMD harbors
a neutral hemizygous variant in the affected Fam2 indi-
vidual, a gene where recessive variants can cause muscle
dystrophy; DAG1 and MKKS are associated with reces-
sive diseases, yet the variants in the affected individuals
are heterozygous; IRF1 is associated with non-cardiac
diseases; DSC1, a desmosomal gene not associated with
heart disease, harbors a common missense variant that
is predicted neutral. Since all of these genes are interest-
ing candidates for follow up studies, it would be interest-
ing to test whether the same or other rare variants in
our candidate genes can be identified in a large cohort
ACM patients, both in patients carrying desmosomal
mutations or other ACM related mutations as well as in
genetically unsolved cases.
Digenic inheritance has previously been reported as a
disease-causal mechanism for ACM, however, these
studies have focused on desmosomal genes. As a result,
there are no reports of digenic inheritance in ACM with
PKP2 and a non-desmosomal gene such as TTN.
We are aware of limitations in our study. Both families
have relatively few members, which resulted in a large set
of variants and genes as possible candidates for digenic in-
heritance. Only 85% of the exome was covered with at least
10X. Since we required a minimum coverage of 10X to
accept a variant call, 15% of the exome could not be investi-
gated. However, coverage at the ACM genes was well above
average, so it is unlikely that variants were missed in these
genes. Due to the large number of candidate genes in each
family, we restricted our analysis to ACM or PKP2-related
genes, potentially removing causative digenic genes with
unknown associations. Even though the TTN variants in
Fam2 were confirmed by Sanger sequencing, no functional
validation of the variant effects was performed. Therefore,
it still needs to be shown if TTN or any of the candidate
genes in Fam1 truly cause ACM together with PKP2 in the
respective family. A functional validation could be per-
formed based on induced pluripotent stem cell (iPSC)
models from the ACM-affected individuals, where the
PKP2 variant or the TTN/Fam1 variants are reversed [53].
In the iPSC derived cardiomyocytes the effect of the genetic
variants could be investigated by comparing fat accumula-
tion and cell electrophysiology to the double mutant cells.
Other cell models that could be employed for validation are
progenitor cells (they differentiate easily in vitro), non-
contractile cardiac mesenchymal stromal cells (ideal for
studying lipid metabolism), or primary or immortalized car-
diomyocytes (enable investigation of gap-junctions and ion-
channels) [54]. Yet, even if successful, such experiments
would demonstrate the mode of effect in the respective
family, while general conclusions about the role of TTN/
Fam1 genes in ACM could not necessarily be drawn from
them. To evaluate the roles of these genes in ACM more
generally, other ACM patients carrying desmosomal vari-
ants could be checked for rare variants in the respective
genes. Unfortunately, we currently do not have additional
ACM patients for testing and the NCBI Sequence Read
Archive does not contain public whole exome or whole
genome sequence data of ACM patients. The search for
genes with a digenic effect is a considerable challenge since
variants in both relevant genes do not necessarily have a
pathogenic effect when occurring individually [11]. The
functional or structural change caused by the variant in ei-
ther protein may be subtle, and may for example lead to a
change at a protein binding affinity or a change in gene ex-
pression. Therefore, standard criteria usually applied to
evaluate the likelihood of variant pathogenicity like rarity
and computational predictions might not be well suited.
Consequently, we did not exclude variants based on these
criteria, yet in the absence of functional validation and
more appropriate models, we prioritized and discussed our
results according to these methods. We would like to recall
that we did not distinguish between variants that were
present in the affected and not in the carriers and variants
present in the carriers but not in the affected, since we were
interested in genes whose function might differ between af-
fected individuals and carriers due to the variants. However,
we point out that of the 17 variants listed in Table 2, only
three (Ile339Val in MKKS, His558Arg in SCN5A, and
Ser321Leu in DROSHA) are present in the carriers and not
in the affected individuals, suggesting that our strategy of
prioritizing based on rarity and predicted pathogenicity is
appropriate. Finally, we acknowledge the possibility that
more than two genes could be involved in the pathogenesis
(oligogenic inheritance) or, contrarily, that environmental
factors could influence the penetrance of the PKP2 variants
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without other genetic variants having an effect on the de-
velopment of ACM. However, in our study, the main non-
genetic disease modulators (age, sex, and physical exercise)
are not sufficient to explain the different phenotypic ex-
pression in affected individuals and carriers in the two ana-
lyzed families (see Table 1). In Fam1, both the carrier
Fam1.III.1 and the affected Fam1.III.2 are male and are
close in age, and carrier Fam1.III.1 and the affected Fam1.-
III.3 are both physically active. In Fam2, both the affected
Fam2.II.1 and the carrier Fam2.II.2 are male, physically ac-
tive, and relatively close in age.
Conclusions
In the present work we have provided further indication
that a single (desmosomal) mutation might not be sufficient
to cause ACM, by showing the co-segregation of other vari-
ants with PKP2 and the phenotype in two families.
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